Brown: Risk Weighti...
Health Care: Drugs
Curis Inc. (CRIS: NASDAQ)
$4.12 0.11 | 2.74%
05/17/13 - 04:00 PM ET
707.95K / 563.90K
Vol / Avg. Vol:4.05 / 4.01
Open / Prev. Close:3.98 - 4.17
Today's Range:2.66 - 5.51
52 Wk Range:16.91%
Performance YTD:TheStreet Rating:
Portfolios with CRIS
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Userwjwallace Portfolio
- Contributor5 Stocks to Watch Under $5
- ContributorStocks At New 52-Week Highs...
- ContributorBreakout Stocks Of The Week...
- UserMontana Nugget
- ContributorCancer Drug Stocks to Trade...
- Usermoney II
- Usermoney
Latest CRIS Headlines from TheStreet
- Curis To Present At The BioCentury Future Leaders In The Biotech Industry Conference 03.29.13 | 07:03 am
- 16 Stocks Under $5 Trading At Discounts To Target Price 03.26.13 | 12:03 pm
- Curis Announces Appointment Of Kenneth Pienta, M.D. To Board Of Directors 03.11.13 | 08:03 am
- Curis To Present At The Roth Capital Partners 25th Annual Growth Stock Conference 03.11.13 | 07:03 am
- Curis To Present At The Cowen And Company 33rd Annual Health Care Conference 02.25.13 | 07:02 am
- Curis Reports Fourth Quarter And Year-End 2012 Financial Results 02.20.13 | 07:02 am
- Curis Appoints Ali Fattaey, Ph.D. As President And Chief Operating Officer 02.19.13 | 07:02 am
- Curis To Present At Upcoming Investor Conferences 02.15.13 | 07:02 am
- Curis To Release Fourth Quarter And Year End 2012 Financial Results And Hold Conference Call On February 20, 2013 02.13.13 | 07:02 am
- Curis Announces Dosing Of First Patient In Phase I Clinical Trial Of Dual PI3 Kinase And HDAC Inhibitor CUDC-907 01.24.13 | 07:01 am
Press Releases for CRIS
- Debiopharm And Curis Announce Initiation Of Phase Ib Expansion Study Of HSP90 Inhibitor Debio 0932 - PR Newswire 02.16.12 | 07:02 am
- Curis Announces Collaborator Roche’s Submission Of Marketing Authorization Application For Vismodegib In Advanced Basal Cell Carcinoma - Business Wire 12.22.11 | 07:12 am
- Curis To Present At The Oppenheimer & Company’s 22nd Annual Healthcare Conference - Business Wire 12.06.11 | 07:12 am
- Curis Announces Agreement With The Leukemia & Lymphoma Society To Develop CUDC-907 For Lymphoma And Multiple Myeloma - Business Wire 11.30.11 | 07:11 am
- Curis To Present At Piper Jaffray 23rd Annual Healthcare Conference - Business Wire 11.23.11 | 08:11 am
- Curis Presents Data On PI3K And HDAC Inhibitor CUDC-907 At The 2011 AACR-NCI-EORTC Symposium - Business Wire 11.16.11 | 08:11 am
- Curis Announces FDA Acceptance And Priority Review Of NDA For Vismodegib As Treatment For Advanced Basal Cell Carcinoma - Business Wire 11.09.11 | 01:11 am
- Curis Announces Appointment Of Maurizio Voi, M.D. As Chief Medical And Chief Development Officer - Business Wire 11.08.11 | 07:11 am
- Curis To Present At The Lazard Capital Markets Healthcare Conference - Business Wire 11.07.11 | 04:11 pm
- Curis Reports Third Quarter 2011 Financial Results - Business Wire 10.27.11 | 07:10 am
Partner Headlines for CRIS
- AACR Annual Oncology Meeting: A Look Into Various Abstracts - Seeking Alpha 03.27.12 | 09:03 am
- Rodman & Renshaw Outperform On Curis, Inc. - Benzinga 06.21.11 | 01:06 pm
- Positive Data on Roche's BCC Drug - Analyst Blog - Zacks 06.21.11 | 10:06 am
- Morning Market Movers (CRIS, OXPS, SMIT, TGE) - Benzinga 03.21.11 | 09:03 am
- Zacks #5 Rank Additions for Monday - Tale of the Tape - Zacks 02.14.11 | 09:02 am
- UPDATE 2-Curis says Roche seeks more analysis of cancer drug - Reuters 08.09.10 | 01:08 pm
- UPDATE 4-Curis says cancer drug fails in mid-stage trial - Reuters 06.16.10 | 02:06 pm
- Curis, Roche drug combats children's brain tumors - Reuters 06.05.10 | 09:06 am
- 4 Stocks to Watch at ASCO - Seeking Alpha 06.02.10 | 07:06 am
- 2 Smallcap Biotech Stocks to Watch - SeekingAlpha.com 04.20.10 | 01:04 am
